This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tse, A. N. Articles by Schwartz, G. K. Search for Related Content PubMed PubMed Citation Articles by Tse, A. N. Articles by Schwartz, G. K.

Targeting Checkpoint Kinase 1 in Cancer Therapeutics

Authors' Affiliations: ¹ Gastrointestinal Oncology Service and ² Melanoma and Sarcoma Service, Division of Solid Tumor Oncology and ³ Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York

Requests for reprints: Archie N. Tse, Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021. Phone: 212-639-8324; Fax: 212-717-3320; E-mail: tsea{at}mskcc.org.

Abstract

Progression through the cell cycle is monitored by surveillance mechanisms known as cell cycle checkpoints. Our knowledge of the biochemical nature of checkpoint regulation during an unperturbed cell cycle and following DNA damage has expanded tremendously over the past decade. We now know that dysfunction in cell cycle checkpoints leads to genomic instability and contributes to tumor progression, and most agents used for cancer therapy, such as cytotoxic chemotherapy and ionizing radiation, also activate cell cycle checkpoints. Understanding how checkpoints are regulated is therefore important from the points of view of both tumorigenesis and cancer treatment. In this review, we present an overview of the molecular hierarchy of the checkpoint signaling network and the emerging role of checkpoint targets, especially checkpoint kinase 1, in cancer therapy. Further, we discuss the results of recent clinical trials involving the nonspecific checkpoint kinase 1 inhibitor, UCN-01, and the challenges we face with this new therapeutic approach.

This article has been cited by other articles:

				H. Gali-Muhtasib, D. Kuester, C. Mawrin, K. Bajbouj, A. Diestel, M. Ocker, C. Habold, C. Foltzer-Jourdainne, P. Schoenfeld, B. Peters, et al. Thymoquinone Triggers Inactivation of the Stress Response Pathway Sensor CHEK1 and Contributes to Apoptosis in Colorectal Cancer Cells Cancer Res., July 15, 2008; 68(14): 5609 - 5618. [Abstract] [Full Text] [PDF]

				S. Ashwell and S. Zabludoff DNA Damage Detection and Repair Pathways--Recent Advances with Inhibitors of Checkpoint Kinases in Cancer Therapy Clin. Cancer Res., July 1, 2008; 14(13): 4032 - 4037. [Abstract] [Full Text] [PDF]